
KNSA Stock Forecast & Price Target
KNSA Analyst Ratings
Bulls say
Kiniksa Pharmaceuticals is a strong investment opportunity, with its established and growing revenue stream from its key product Arcalyst and promising pipeline candidates, indicating potential for continued growth. Additional growth initiatives and strong commercial momentum also support the company's long-term outlook. However, there are risks to consider, such as potential competition and challenges in commanding premium pricing for rare disease treatments. Overall, with a strong management team and a solid financial position, the company is well-positioned for success in the biopharmaceutical market.
Bears say
Kiniksa Pharmaceuticals is currently focused on phase 2 dose-finding data expected in the second half of 2026 and plans to initiate a pivotal phase 3 study by the end of 2026 for KPL-387, a once-monthly treatment for recurrent pericarditis. Additionally, the delay in competition from LLY widens KNSA's competitive runway for their drug candidates. The company's current stock price of $59 is derived from a sum-of-parts valuation for their clinical programs, including an 8x multiple to their share of estimated US sales for Arcalyst in RP and CAPS in 2028, and an 8x multiple to estimated sales for KPL-387 in RP in 2032. While Arcalyst is currently profitable, the potential success of their next-generation RP assets could lead to further profitability and upside for the company's stock.
This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
KNSA Analyst Forecast & Price Prediction
Start investing in KNSA
Order type
Buy in
Order amount
Est. shares
0 shares